Monopar Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.62, missing the estimate of USD -0.5709.

EBIT: As of FY2026 Q2, the actual value is USD -6.613 M.

Monopar Therapeutics Inc. reported that specific financial and operational metrics, including segment revenue, gross margin, operating profit, operating costs, and cash flow, were not detailed within the provided Form 8-K filing .

Cash, Cash Equivalents, and Investments

As of June 30, 2026, Monopar Therapeutics Inc. held $134.3 million in cash, cash equivalents, and investments .

Net Loss

For the second quarter of 2026, the net loss was $5.3 million, or $0.62 per share, compared to a net loss of $2.5 million, or $0.35 per share, for the second quarter of 2025 .

Research and Development (R&D) Expenses

R&D expenses for the second quarter of 2026 totaled $4,766,832, an increase of $3,036,831 from $1,730,000 in the second quarter of 2025 . This increase was primarily driven by a $2,026,851 rise in R&D contractor and consulting expenses, a $721,228 increase in R&D personnel expenses (including stock-based compensation), and a net increase of $288,752 in other R&D expenses .

General and Administrative (G&A) Expenses

G&A expenses for the second quarter of 2026 were $1,877,831, an increase of $373,536 from $1,504,295 in the second quarter of 2025 . This rise was mainly due to a $234,113 increase in G&A personnel expenses (including stock-based compensation) and a $198,988 increase in G&A contractor and consulting expenses, partially offset by a net decrease of $59,565 in other G&A expenses .

Other Income (Loss)

Other income for the second quarter of 2026 was $32,158, compared to $0 for the second quarter of 2025, primarily due to an adjustment to a vendor invoice .

Interest Income (Loss)

Interest income for the second quarter of 2026 was $1,299,205, an increase from $780,769 in the second quarter of 2025 . This increase is attributed to interest earned on U.S. Treasury securities and commercial paper, and higher bank balances following approximately $91.9 million in net proceeds from a September 2025 capital raise .

Outlook

Monopar Therapeutics Inc. expects to complete its ALXN1840 New Drug Application (NDA) submission within the next few months and is preparing for a potential commercial launch . The company’s current funds are anticipated to support operations through at least December 31, 2027, covering regulatory and potential commercial activities for ALXN1840, continued development of MNPR-101 programs, and internal research and development . The Rare Pediatric Disease designation for ALXN1840 offers the potential to receive a pediatric Priority Review Voucher upon NDA approval .